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THE PATENT ON-SALE BAR POSTHELSINN AND ITS EFFECT ON THE
PHARMACEUTICAL INDUSTRY
BY
Raja Chatterjee*
ABSTRACT
The purpose of the patent on-sale bar is to discourage inventors from
misusing the patent system and unfairly extending their patent exclusivity
period. In Helsinn Healthcare v. Teva Pharmaceuticals, the Federal Circuit
has distorted this doctrine far beyond its purpose. By including non-public
business transactions within the scope of the on-sale bar, the Federal
Circuit’s decision contradicts legislative history and express statutory
language from the America Invents Act (“AIA”). This interpretation also
makes the U.S. the only major patent system where a non-public sale can
lead to the forfeiture of an inventor’s patent rights.
The inclusion of non-public agreements within the scope of invalidating
prior-art is a particularly harsh result for small pharmaceutical companies.
These companies routinely enter into private license and supply agreements
both to raise capital and to ally with experienced industry players who can
help them navigate through the challenging FDA approval process. The
Federal Circuit’s Helsinn decision restricts the ability of small
pharmaceutical companies to collaborate with others, and therefore impedes
*

Raja Chatterjee graduated summa cum laude from SMU Dedman School of Law
in May 2018 with a J.D. degree and is now an associate at Akin Gump Strauss
Hauer and Feld. He has a Master’s degree in Mechanical Engineering from
Stanford University and has worked extensively in the design and manufacture of
implantable medical devices.

207

208

CHICAGO-KENT JOURNAL OF INTELLECTUAL PROPERTY

Vol 18:1

their ability to innovate. Helsinn also makes the on-sale bar inquiry
extremely fact-specific and injects unnecessary uncertainty into routine
business deals.
This paper suggests that the Federal Circuit’s decision in Helsinn
misinterprets the AIA’s statutory text, ignores significant legislative history,
and is logically at odds with the economic realities of the pharmaceutical
industry. This paper also provides some practical suggestions for how
pharmaceutical companies can structure commercial transactions without
stepping on the on-sale bar minefield.
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I. INTRODUCTION
The Federal Circuit’s recent application of the on-sale bar1 is unmoored
from the doctrine’s original purpose2- to prevent inventors from misusing the
patent system and unfairly removing inventions from the public domain. In
holding that private business deals trigger the on-sale bar, even ones that did
not place an invention in the public domain, the Federal Circuit has turned
the on-sale bar into a trap for the unwary. As evidenced by a spate of recent
cases,3 the Federal Circuit’s flawed approach to the on-sale bar has been
especially disruptive for the pharmaceutical (“pharma”) industry. Due to the
high cost and complexity of drug development, pharma companies
frequently enter into early-stage business partnerships to fund their research
activities. These partnerships often take the form of license and supply
agreements.4 The Federal Circuit’s expansive interpretation classifies many
of these private agreements as a “sale” for purpose of the on-sale bar.5 A
“sale” initiates a one-year countdown from the time of the agreement and
invalidates future patents if an application is not filed within one year. Many
of the companies entering into such license or supply agreements do not
recognize the ticking one-year clock, as they do not realize that their
innocuous business agreements were a “sale” of their inventions. This puts
pharma companies at risk of losing out on patent protection after spending a
significant amount of money and time in developing their inventions.6 This
outcome is exceptionally disastrous as they rely heavily on market
exclusivity provided by the patent system to recoup their high up-front
development expenses. By making it harder for small pharma companies to
continue innovating, the Federal Circuit’s interpretation is detrimental to
“the progress of science and useful arts.”7 This paper further argues that not
only is the Federal Circuit’s interpretation detrimental to the pharma

1. See Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc., 855 F.3d 1356, 1371 (Fed. Cir. 2017).
2. In re Mahurkar Double Lumen Hemodialysis Catheter Patent Litig., 71 F.3d 1573, 1577 (Fed.
Cir. 1995).
3. See Helsinn Healthcare S.A., 855 F.3d at 1371; Merck & Cie v. Watson Labs., Inc., 822 F.3d
1347, 1355 (Fed. Cir. 2016); Abbott Labs. v. Geneva Pharm., Inc., 182 F.3d 1315, 1319 (Fed. Cir. 1999);
C.R. Bard, Inc. v. M3 Sys., Inc., 157 F.3d 1340, 1375–76 (Fed. Cir. 1998).
4. See David Thomas & Chad Wessel, Emerging Therapeutic Company Investment and Deal
Trends,
BIO,
32
(May
2018),
http://go.bio.org/rs/490-EHZ999/images/BIO%20Emerging%20Therapeutics%20Company%20Investment%20and%20Deal%20Tre
nds%20Report%202008-2017.pdf?_ga=2.45656556.936831433.1543089094-905210238.1524285270.
5. See, e.g., Helsinn Healthcare S.A., 855 F.3d at 1371.
6. See, e.g., id.
7. U.S. CONST. art. I, § 8, cl. 8.

2019

THE PATENT ON SALE BAR POST HELSINN AND ITS EFFECT

211

industry, it also misinterprets statutory text and ignores significant legislative
history.
The original intent of the on-sale bar was straightforward.8 The U.S.
patent system is an elaborate quid-pro-quo system where the inventor offers
to publicly disclose the invention in return for a period of exclusivity granted
by the patent. An inventor who has already made an invention available to
the public by selling it has nothing more to offer in return for the grant of a
patent. Therefore, the on-sale bar prevents an inventor from obtaining a
patent if the invention was publicly on-sale for more than a year before filing
the patent application. The one-year grace-period provides the inventor with
some leeway to assess the viability of the invention before filing the patent
application. The on-sale bar also intends to prevent the prejudicial removal
of “existing knowledge from public use.”9 Judicial interpretations have, over
time, warped this simple doctrine to its current form where the doctrine is
unnecessarily expansive and penalizes even those business deals that do not
make an invention publicly available. Part II of this paper discusses the
historical underpinnings of the modern on-sale bar, the attempt to fix the
doctrine through the AIA, and the Federal Circuit’s refusal to acknowledge
Congress’ statutory fix in Helsinn Healthcare v. Teva Pharm.10
While other scholars have commented on the on-sale bar in general,
Part III of this paper identifies some unique issues that this doctrine presents
to the pharma industry, especially smaller companies. The Helsinn decision
hamstrings the ability of small pharma companies to raise money for earlystage research. Post-Helsinn, pharma companies need to be much more
cautious about structuring agreements to avoid inadvertently triggering the
on-sale bar.
Part IV of this paper analyzes the changes made by the AIA to 35 U.S.C.
§ 102(a) and its impact on the scope of on-sale bar. AIA added the phrase
“or otherwise available to the public” to the definition of “prior art” in U.S.C.
§ 102(a)(1).11 This addition signals Congress’ intent to remove non-public
business deals from the ambit of the on-sale bar. Floor statements from the
sponsors of the AIA, as well as excerpts from the Congressional report,
confirm that the updated on-sale-bar applies only to “public sales.”12 This
section, therefore, argues that the Federal Circuit’s interpretation of the on-

8. See In re Mahurkar Double Lumen Hemodialysis Catheter Patent Litig., 71 F.3d 1573, 1577
(Fed. Cir. 1995).
9. Pfaff v. Wells Elecs., Inc., 525 U.S. 55, 64 (1998).
10. Helsinn Healthcare S.A., 855 F.3d at 1371.
11. 35 U.S.C. § 102 (2012).
12. 157 CONG. REC. 3415 (2011).
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sale bar is at odds with updated statutory text and defies compelling
legislative history.
Part V recognizes that until further guidance is received from the
Supreme Court, the Federal Circuit’s interpretation is controlling for future
on-sale bar cases. It summarizes observations from recent Federal Circuit
case-law to provide suggestions for small pharma companies. It also suggests
ways to structure business transactions that may avoid setting off the on-sale
bar minefield.
II. HISTORICAL DEVELOPMENT OF THE ON-SALE BAR DOCTRINE
A. THE STATUTE IS SIMPLE AND LOGICAL
The statutory on-sale bar was first enacted by Congress in 1839.13 It
prevented inventors from obtaining a patent if they had placed their invention
“on-sale” or in “public use,” for more than two years before filing the patent
application. 14 The grace period was changed to one year in 1939, as it
remains to-date. 15 The purpose of the doctrine was simple: it prevented
inventors from removing inventions from the public sale after the public
reasonably believed the invention to be in public space.16 The forfeiture of
the inventor’s patent rights was a direct result of their decision to place the
invention on-sale or in public use for an extended period of time. The
doctrine also encouraged the early filing of patents and discouraged
inventors from keeping their invention secret to unfairly extend the
exclusivity period. 17 The basics of the on-sale bar remained largely
unchanged from 1939 until the 2012 enactment of the AIA. Judicial
interpretation of the statute has, however, varied dramatically over time.
B. COURTS HAVE STRUGGLED TO APPLY THE ON-SALE BAR
DOCTRINE
The primary struggle for courts has been to define when an invention is
“on-sale” for the purpose of the statute. The earliest and most straightforward

13. Patent Act of 1839, ch. 88, § 7, 5 Stat. 353, 354 (1839).
14. Id.
15. Patent Act of 1939, ch. 450, § 1, 53 Stat. 1212 (1939).
16. Erol C. Basol, Fabless Semiconductor Companies, the Patent On Sale Bar, and the New
America Invents Act: Have Fabless Companies Been Shortchanged, or Is Change Coming?, 16 UCLA
J.L. & TECH. 1, 7 (2012).
17. Mark Levy, An Analysis of the On Sale Bar and Its Impact on the Structure and Negotiation of
Development Agreements, 30 U. DAYTON L. REV. 181, 183 (2004).
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answer to this question was the “on-hand” rule.18 To trigger the on-sale bar,
the on-hand rule required an invention to be physically manufactured and
available for sale a year before the patent application was filed.19 Concern
that inventors would delay physically manufacturing the inventive product
to unfairly extend their exclusivity period led courts to de-link physical
reduction to practice from the application of on-sale bar. 20 However,
defining when a product that did not physically exist was “on-sale” proved
to be a slippery task for appellate courts. The Federal Circuit cycled through
the “totality of circumstances test,”21 the “completed invention test,”22 and
the “substantially complete test”23 in quick succession. Frequent reversals by
the Federal Circuit, and ensuing confusion in lower courts, convinced the
Supreme Court to grant certiorari in Pfaff v. Wells Electronics, Inc.24 In Pfaff,
the Supreme Court created a new two-prong test for the application of the
on-sale bar.25 The first prong requires an invention to be the subject of a
“commercial offer for sale,” 26 and the second prong requires that the
invention be “ready for patenting.”27
The Pfaff test has, at best, had limited success in reducing confusion
about when the on-sale bar is triggered. At times, the Federal Circuit found
that the “ready for patenting” prong is satisfied without proof of
conception, 28 and at other times, it has required both conception and
reduction to practice. 29 Interpretation of the “commercial offer for sale”
prong has not fared much better. In some cases, the Federal Circuit has
looked at the Uniform Commercial Code (“UCC”) to define when a sale
occurs.30 In other cases, it has relied on the usage of trade and course of
dealing within a specific industry.31 In Special Devices, Inc. v. OEA, Inc., the
Federal Circuit held that there is no “supplier” exception to the on-sale bar,

18. McCreery Eng’g Co. v. Mass. Fan Co., 195 F. 498, 501 (1st Cir. 1912) (noting the substantial
difference between “an executory contract to construct and to pass title in the future and putting an article
‘on sale’”).
19. Id. at 501–02.
20. UMC Elecs. Co. v. United States, 816 F.2d 647, 655–56 (Fed. Cir. 1987).
21. Id. at 656.
22. Seal-Flex, Inc. v. Athletic Track & Court Constr., 98 F.3d 1318, 1324 (Fed. Cir. 1996).
23. Micro Chem., Inc. v. Great Plains Chem. Co., 103 F.3d 1538, 1545 (Fed. Cir. 1997).
24. Pfaff v. Wells Electronics, Inc., 525 U.S. 55, 60 (1998).
25. Id. at 67–68.
26. Id. at 67.
27. Id. at 68.
28. Abbott Labs. v. Geneva Pharm., Inc., 182 F.3d 1315, 1318 (Fed. Cir. 1999).
29. Robotic Vision Sys. v. View Eng’g, Inc., 249 F.3d 1307, 1313 (Fed. Cir. 2001).
30. Lacks Indus. v. McKechnie Vehicle Components USA, Inc., 322 F.3d 1335, 1347 (Fed. Cir.
2003).
31. Cargill, Inc. v. Canbra Foods, Ltd., 476 F.3d 1359, 1370 (Fed. Cir. 2007).
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and an outsourced manufacturing agreement was an invalidating “sale.”32 In
Medicines Co. v. Hospira, 33 the Federal Circuit reached the opposite
conclusion en banc and found that a manufacturing agreement did not
involve title transfer and therefore did not trigger the on-sale bar. Congress
attempted to ameliorate this inconsistent application of the on-sale bar
through the AIA.34
C. AIA ATTEMPTS TO SIMPLIFY THE ON-SALE BAR
The AIA, enacted in September 2012, is the most comprehensive
reform of the U.S. patent system in decades. This legislation affected the onsale bar through an update to the definition of “prior art.” The AIA defines
prior-art as inventions that are “patented, described in a printed publication,
or in public use, on sale, or otherwise available to the public before the
effective filing date of the claimed invention.”35 While the definition uses
terms similar to the pre-AIA definition, the addition of the phrase “or
otherwise available to the public. . .” has been considered significant.
Commentators, some of whom were involved in drafting the AIA, thought
that this phrase removed secret-sales from the scope of the on-sale bar.36
They also believed that the policy intent of the on-sale bar was better served
by removal of secret-sales from its scope.37 Requiring public knowledge also
makes it easier to identify the critical date when the invention is placed onsale, for purpose of the statute, thus providing more certainty to inventors.38
D. USPTO EMBRACES THE NEW ON-SALE BAR
The United States Patent and Trademark Office (“USPTO”) embraced
the modified scope of on-sale bar by updating the Manual of Patent
Examining Procedure (“MPEP”). The updated MPEP states: “The phrase ‘on
sale’ in AIA 35 U.S.C. § 102(a)(1) is treated as having the same meaning as
32. Special Devices, Inc. v. OEA, Inc., 270 F.3d 1353, 1355 (Fed. Cir. 2007).
33. Meds. Co. v. Hospira, 827 F.3d 1363, 1375 (Fed. Cir. 2016).
34. Leahy-Smith America Invents Act, Pub. L. No. 112-29, 125 Stat. 284 (2011).
35. 35 U.S.C. § 102(a) (2012) (emphasis added).
36. Joe Matal, A Guide to the Legislative History of the America Invents Act: Part I of II, 21 FED.
CIR. B.J. 435, 467 (2012); Robert A. Armitage, Understanding the America Invents Act and Its
Implications for Patenting, 40 AIPLA Q.J. 1, 53 (2012); Dmitry Karshtedt, Did Learned Hand Get It
Wrong?: The Questionable Patent Forfeiture Rule of Metallizing Engineering, 57 VILL. L. REV. 261, 332
(2012).
37. See also Iftikhar Ahmed, What They Don’t Know Shouldn’t Hurt You: Adding a Public
Knowledge Prong to the On-Sale Bar Helps Provide Certainty to Inventors and Competitors Alike, 45
HOUS. L. REV. 153, 182–83 (2008).
38. Id. at 185 (“Inventors could clearly identify the critical date because they will know if their sale
has resulted in any public knowledge.”).
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‘on sale’ in pre-AIA 35 U.S.C. § 102(b), except that the sale must make the
invention available to the public.”39 Examination guidelines stated that “the
Office views the ‘or otherwise available to the public’ residual clause of the
AIA’s 35 U.S.C. § 102(a)(1) as indicating that secret sale or use activity does
not qualify as prior art.”40 Since this update to the MPEP, countless patents
have been granted by the USPTO, many of them relying on the updated
interpretation of the on-sale bar.41 A controversy related to drug patents, and
the tussle between novel and generic drug manufacturers, soon invited
judicial review of this interpretation.42
E. HELSINN V. TEVA TESTED THE UPDATED INTERPRETATION OF
THE ON-SALE BAR
The post-AIA interpretation of the on-sale bar was challenged in a drug
patent case where the Federal Circuit reversed both the USPTO and the
District Court of New Jersey to hold that the AIA did not modify the prior
understanding of the on-sale bar statute. 43 It held that private business
agreements can still trigger the on-sale bar.44
Helsinn is a small family-run pharma company that focuses on the
development of drugs for the treatment of cancer symptoms. 45 In 1998,
Helsinn paid drug giant Roche $10 million to buy the patent for the
compound palonosetron.46 Helsinn, after extensive research and a phase III
clinical study, created a stable formulation using this compound.47 The FDA
approved this formulation as the drug Aloxi® to relieve nausea symptoms for
patients undergoing chemotherapy.48 Helsinn almost ran out of funds during
the expensive development process and entered into a license and supply
agreement with another small company, MGI, to raise additional money.
39. DEP’T OF COMMERCE, PATENT & TRADEMARK OFFICE, MANUAL OF PATENT
EXAMINING PROCEDURE § 2152.02(d) (9th ed. Rev. 1, Nov. 2013) (emphasis added).
40. Examination Guidelines for Implementing the First Inventor To File Provisions of the LeahySmith America Invents Act, 78 Fed. Reg. 11059, 11062 (Feb. 14, 2013).
41. Brief for Pharmaceutical Research and Manufacturers of America as Amicus Curiae Supporting
Petitioners at 7, Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc., 2018 WL 1583031 (Fed. Cir. 2017)
(Nos. 16-1284, 16-1787), 2017 WL 3208579.
42. Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc., 855 F.3d 1356 (Fed. Cir. 2017).
43. Id. at 1371.
44. Id.
45. Our Mission and Values, HELSINN, https://www.helsinn.com/about-us/our-mission-and-values/
(last visited Apr. 28, 2018).
46. Transcript of Trial, Helsinn Healthcare S.A. v. Dr. Reddy’s Labs., Ltd., 2015 WL 13404191
(D.N.J. 2015) (No. 11-3962).
47. Brief of Plaintiffs-Appellees at *4–6, Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc., Nos.
16-1284, 16-1787 (Fed. Cir. Apr. 25, 2016), 2016 WL 1698099.
48. Id. at *2.
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MGI agreed to pay an upfront license fee in return for exclusive rights to
market the final drug upon approval by the FDA.49 Helsinn also promised to
manufacture and supply the approved drug to MGI.50 The license and supply
agreements had a strict confidentiality clause aimed specifically at keeping
the drug formulation out of public space. 51 MGI, in order to fulfill its
obligations as a public company, disclosed in an SEC filing the fact that it
had entered into an agreement with Helsinn,52 but redacted all confidential
information from the disclosure. Teva Pharmaceuticals approached the FDA
to gain approval for a generic version of Helsinn’s palonosetron
formulation.53 Helsinn, in turn, sued Teva for patent infringement. 54 Teva
challenged the validity of Helsinn’s patents under the on-sale bar doctrine,
as the agreement with MGI had been signed more than a year before Helsinn
filed its patent applications.55 The District Court of New Jersey held that,
since the license and supply agreement did not make the details of the
invention public, it could not form the basis for triggering the on-sale-bar.56
The Federal Circuit reversed the District Court’s holding.57
The Federal Circuit concluded that the AIA had not updated the on-sale
bar to exclude non-public sales. The court reasoned that if Congress wanted
to modify the on-sale bar instead of simply adding a new phrase to the
definition, “it would do so by clear language.” 58 The AIA’s legislative
history, indicating Congressional intent to update the on-sale bar doctrine,
also failed to sway the court’s reasoning. 59 Additionally, Helsinn’s
confidential agreement was found to constitute an “offer for sale” and
triggered the on-sale bar.60 The court stated that post-AIA “if the existence
of the sale is public, the details of the invention need not be publicly
disclosed in the terms of sale”61 to trigger the on-sale bar. After the denial of
a petition for en banc review by the Federal Circuit, Helsinn filed a writ of
49. Id. at *5–7.
50. Id.
51. Id. at *9.
52. MGI
Pharma
Inc.,
Current
Report
(Form
8-K)
(Feb.
13,
2001),
https://www.secinfo.com/dvTEu.465.htm.
53. Helsinn Healthcare S.A. v. Dr. Reddy’s Labs., Ltd., No. CV 11-3962 (MLC), 2016 WL 832089,
at *2 (D.N.J. Mar. 3, 2016), rev’d sub nom. Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc., 855 F.3d
1356(Fed. Cir. 2017).
54. Id. at *1.
55. Id. at *2.
56. Id. at *64.
57. Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc., 855 F.3d 1356, 1371 (Fed. Cir. 2017).
58. Id.
59. Id. at 1368.
60. Id. at 1371.
61. Id.
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certiorari to the U.S. Supreme Court, which has been accepted for hearing in
the next term.
III. THE HELSINN DECISION DISPROPORTIONATELY AFFECTS THE
PHARMA INDUSTRY, ESPECIALLY THE SMALLER COMPANIES
The Helsinn decision can have a significant long-term impact on the
pharma industry. The high up-front cost of drug development, combined
with a long regulatory approval process, leaves the pharma industry
especially susceptible to issues that impact the ability to raise capital and
protect intellectual property. The Helsinn decision hurts the pharma industry,
especially small companies on both fronts.
A. SMALL PHARMA COMPANIES ARE INNOVATIVE AND SERVE AN
IMPORTANT PURPOSE
The pharma industry is a vibrant source of innovation that provides
hope and relief to millions of patients around the world. Expected to grow at
an impressive rate of five percent over the next five years, the global pharma
industry is expected to be worth $8.7 trillion by 2020.62 Contrary to popular
belief, not all pharma companies are multi-billion-dollar behemoths. About
66 percent of the drugs approved by the FDA in recent years came from
small and mid-size companies.63 The ability of smaller pharma companies to
take on more risk allows them to work, not only on potential blockbuster
drugs, but also those aimed at rare diseases.64 A case in point is Aloxi®, the
drug that was the subject of the Helsinn case. A large pharmaceutical
company, Roche, deemed the formulation too risky after unfavorable Phase
II clinical study results. 65 Helsinn, a small family owned drug company,
stepped in and acquired the formula from Roche.66 It completed Phase III
trials, obtained FDA approval, and brought the drug to market to help
patients undergoing chemotherapy.67

62. Greg
Reh,
2018
Global
Life
Sciences
Outlook,
DELOITTE,
https://www2.deloitte.com/global/en/pages/life-sciences-and-healthcare/articles/global-life-sciencessector-outlook.html (last visited Apr. 28, 2018).
63. Jennifer Alsever, Big Pharma Innovation in Small Places, FORTUNE (May 13, 2016),
http://fortune.com/2016/05/13/big-pharma-biotech-startups/.
64. See Syed Husain & Catherine Hanley, Supporting the Pharma Industry Small Business Growth
Engine, PHARMA’S ALMANAC, https://www.pharmasalmanac.com/articles/supporting-the-pharmaindustry-small-business-growth-engine (last visited Apr. 28, 2018).
65. Brief of Plaintiffs-Appellees at *3–4, Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc., 2016
WL 1698099 (Fed. Cir. 2016).
66. Id. at *4.
67. Id. at *4–5.
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Thus, small drug companies promote innovation. They also fulfill an
important social purpose by working on drugs that larger companies consider
too risky. They, however, often lack the financial strength and regulatory
knowledge to take their innovations to the market without entering into
partnerships with larger companies. Patent laws should help these companies
by making it easier to protect and commercialize inventions. Helsinn does
the opposite.
B. UNCERTAIN PROTECTION OF PATENTS WILL HURT THE PHARMA
INDUSTRY AND PATIENTS
Pharma companies rely heavily on patent protection to recover their
initial investment before the low-cost generics flood the market. A
systematic survey conducted across various research-intensive industries,
showed the pharma industry consistently placed the most importance on
patent protection.68 Protection of patents cannot, however, be at the cost of
the ability to raise money for research. Inventing new drugs is an expensive
business, and the development of a new drug can cost up to $1 billion69 and
15 years of research. 70 The combination of an expensive development
process and a long lead-time to market makes it critical for drug companies
to be able to raise money in early stages of research. Pharma companies often
raise money by entering into licensing and supply agreements with larger
companies. Over the last decade, more than $157 billion was raised by
therapeutic companies through early R&D stage licensing and acquisition
deals. 71 Smaller pharmaceutical companies gain a substantial additional
advantage by allying with larger companies which can help them navigate
the clinical trial and FDA approval process. A study conducted to evaluate
the determinants of success for clinical trials found that a company’s
experience with clinical trials has a strong positive correlation with its
chance of succeeding in meeting the end-points for a clinical trial.72

68. Richard C. Levin et al., Appropriating the Returns from Industrial Research and Development,
3 BROOKINGS PAPERS ON ECON. ACTIVITY, 783, 796–97 (1987).
69. Daniel Wheadon et al., Finance Transformation in the Pharmaceutical Industry, RSM (Mar.
2014),
http://rsmus.com/content/dam/mcgladrey/pdf_download/wp_finance_transformation_pharmaceutical_in
dustry.pdf.
70. Id.
71. See David Thomas & Chad Wessel, Emerging Therapeutic Company Investment and Deal
Trends,
BIO,
5
(May
2018),
http://go.bio.org/rs/490-EHZ999/images/BIO%20Emerging%20Therapeutics%20Company%20Investment%20and%20Deal%20Tre
nds%20Report%202008-2017.pdf?_ga=2.45656556.936831433.1543089094-905210238.1524285270.
72. Patricia M. Danzon et al., Productivity in Pharmaceutical–Biotechnology R&D: The Role of
Experience and Alliances, 24 J. HEALTH ECON. 317, 332, 337 (2005) (noting that large pharma companies
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Helsinn’s interpretation of the on-sale bar doctrine penalizes business
deals that companies use routinely to secure early-stage investment.73 It also
injects unnecessary uncertainty 74 into otherwise routine business
transactions and makes it harder for companies to structure investment deals
without the risk of triggering the on-sale bar.
While filing a patent application earlier into the development process
would presumably resolve the on-sale bar problem, the answer is not so
simple. The long FDA approval process eats into the overall patent
exclusivity period for pharma companies leaving them a shorter amount of
time to recover the initial investment. Therefore, drug manufacturers prefer
to delay filing for a patent until the major clinical trials are complete to
reduce the time gap between the issuance of a patent and the
commercialization of the invention.75 Cost also factors into when a patent
application is filed. A pharma company may assess 200,000 to 1 million
different compounds before one or two viable candidates emerge for the final
drug compound.76 Because the average cost of preparing and filing a patent
is about $60,000, 77 it is impossible for small pharma companies to file
patents for all candidates during the development process.
The Federal Circuit’s interpretation of the on-sale bar not only impacts
pharma companies; it may also hurt patients by discouraging research into
drugs for treating serious illnesses. The ability to protect the patent for a drug
strongly correlates with areas of focus for the pharma industry. Sometimes
this correlation has a perverse impact. An example of this perverse impact
can be seen in recent research related to cancer drugs.78 Between 2009-2014,
eight new cancer treatment drugs arrived on the market.79 All of these drugs
were intended for terminally ill patients in the most advanced stages of
have a 30 percent higher chance of success in clinical trials. Small companies may increase their chance
of success by up to 15 percent if they ally with a large company).
73. See Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc., 855 F.3d 1356, 1371 (Fed. Cir. 2017)
(holding that a confidential license and supply agreement triggered the on-sale bar).
74. See Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc., Nos. 16-1284, 16-1787, 2018 WL
1583031, at *3 (Fed. Cir. Jan. 16, 2018) (O’Malley, J., concurring) (noting that the on-sale bar is a factspecific, case-by-case determination).
75. See generally Eric Budish et al., Do Firms Underinvest in Long-Term Research? Evidence from
Cancer Clinical Trials., 105 AM. ECON. REV. 2044(2015).
76. JP Hughes et al., Principles of Early Drug Discovery, 162 BR. J. PHARMACOL. 1239, 1248
(2011).
77. Russ Krajec, What Do Patents Actually Cost?, BLUEIRON, https://blueironip.com/what-dopatents-actually-cost/ (last visited Apr. 25, 2018).
78. Derek Lowe, Is the Current Patent System Distorting Cancer Research?, IN THE PIPELINE
(August
11,
2014),
http://blogs.sciencemag.org/pipeline/archives/2014/08/11/is_the_current_patent_system_distorting_can
cer_research.
79. Budish et al., supra note 77, at 2044.
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metastasized cancer.80 None of the new drugs that were approved in the same
timeframe targeted treatment of early-stage patients with localized cancers.81
At least one study hypothesized that one possible reason for this difference
might be the length of the clinical study required to obtain approval for such
drugs.82 While drugs targeted at late-stage patients conclude in a few years
as a result of shorter incremental life-expectancy of the subjects, studies
involving earlier stage patients require a longer follow-up period.83 Because
a longer duration of a clinical study essentially means a shorter duration of
the patent-protected exclusivity period, private funding sources are hesitant
to back research that involves early-stage cancer patients.84 As this example
shows, factors that reduce the strength of patent protection for a drug may
also reduce the investment of money into drug development. Since Helsinn
negatively impacts patent protection for new drugs by making it easier to
trigger the on-sale bar, its impact may go beyond just hurting the pharma
industry. Helsinn may end up hurting American patients by reducing the pace
of development for new drugs.
IV. FEDERAL CIRCUIT’S INTERPRETATION DEFIES STATUTORY
TEXT AND LEGISLATIVE HISTORY
The Federal Circuit’s interpretation of the post-AIA on-sale bar belies
plain reading of AIA’s text, undermines Congressional purpose, and is
unsupported by its legislative history.
A. § 102(A) INDICATES THAT THE ON-SALE-BAR APPLIES ONLY TO
INVENTIONS DISCLOSED TO THE PUBLIC
In direct opposition to the AIA’s statutory text, the Federal Circuit in
Helsinn decided that the “Purchase and Supply Agreement” was invalidating
prior art even though it did not make the contents of the invention available
to the public.85 After summarily rejecting the notion that AIA modified the
scope of on-sale bar,86 the Federal Circuit incorrectly relied on pre-AIA case

80.
81.
82.
83.
84.

Id.
Id.at 2045
Id.
Id. at 2045, 2056.
Ray Fisman, Why Aren’t There More Cancer Vaccines? Blame America’s Lousy Patent System,
SLATE
(Aug.
26,
2013,
5:45
AM),
http://www.slate.com/articles/health_and_science/the_dismal_science/2013/08/cancer_treatment_is_am
erican_patent_law_hindering_the_discovery_of_more.html.
85. Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc., 855 F.3d 1356, 1371 (Fed. Cir. 2017).
86. Helsinn Healthcare S.A., 855 F.3d at 1371.

2019

THE PATENT ON SALE BAR POST HELSINN AND ITS EFFECT

221

law. 87 The Helsinn decision spends surprisingly little time on the most
important tool of statutory interpretation: the plain language of the statute.88
The AIA updated 35 U.S.C. § 102(a)(1) to prohibit the issuance of a
patent if “the claimed invention was patented, described in a printed
publication, or in public use, on sale, or otherwise available to the public.”89
As compared to the pre-AIA statute, the phrase “or otherwise available to
the public. . .” is a new addition.90 The textual arguments, in this case, hinge
on the relationship of the term “or otherwise available to the public. . .” in §
102(a)(1) to the preceding term “on sale.”91 The District Court and USPTO
held that the phrase “or otherwise available to the public” is a series-modifier
that modifies the term “on sale.”92 The Federal Circuit panel disagreed.93
This difference in opinion regarding the sentence structure in §
102(a)(1) does not need to be debated on a clean slate. The Supreme Court
has already interpreted a similar sentence structure where it held that “[w]hen
several words are followed by a clause which is applicable as much to the
first and other words as to the last, the natural construction of the language
demands that the clause be read as applicable to all.”94 Even the Federal
Circuit’s own past case law has held that “[w]hen a modifier is set off from
a series of antecedents by a comma, the modifier should be read to apply to
each of those antecedents.” 95 Recognition of the fact that the phrase “or
otherwise available to the public” modifies the meaning of “on sale” leads to
the inevitable conclusion that a sale can only be invalidating when it makes
the claimed invention available to the public. The Federal Circuit’s holding
in Helsinn is therefore inconsistent with the Supreme Court’s previous
holding and the Federal Circuit’s own prior constructions.96
A further indication of Congress’s intent can be gleaned from the
change in title for the statutory section describing the on-sale bar. While pre87. See Pierce Cty. v. Guillen, 537 U.S. 129, 145 (2003) (“[w]hen Congress acts to amend a statute,
we presume it intends its amendment to have real and substantial effect.”).
88. Jimenez v. Quarterman, 555 U.S. 113, 118 (2009); see Helsinn Healthcare S.A., 855 F.3d at
1367–71.
89. 35 U.S.C. § 102 (2012).
90. Helsinn Healthcare S.A., 855 F.3d at 1368.
91. See 35 U.S.C. § 102 (2012).
92. See Helsinn Healthcare S.A. v. Dr. Reddy’s Labs., Ltd., No. CV 11-3962 (MLC), 2016 WL
832089, at *45 (D.N.J. Mar. 3, 2016), rev’d sub nom. Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc.,
855 F.3d 1356 (Fed. Cir. 2017); see also DEP’T OF COMMERCE, PATENT & TRADEMARK
OFFICE, MANUAL OF PATENT EXAMINING PROCEDURE § 2152.02(d) (9th ed. Rev. 1, Nov.
2013).
93. Helsinn Healthcare S.A., 855 F.3d at 1371.
94. Paroline v. United States, 134 S. Ct. 1710, 1721 (2014) (internal citation ommitted).
95. Finisar Corp. v. DirecTV Grp., Inc., 523 F.3d 1323, 1336 (Fed. Cir. 2008) (internal citation
omitted).
96. Helsinn Healthcare S.A., 855 F.3d at 1371.
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AIA section § 102 was titled “Conditions for Patentability; Novelty and loss
of right to patent,” 97 the post-AIA section is titled “Conditions for
Patentability; Novelty.” 98 Removal of the words “loss of right to patent”
signals that the post-AIA statute focuses solely on novelty to define
invalidating prior art. It no longer focuses on actions by inventors that do not
affect novelty but may still result in a loss of the right to a patent. Since sale
agreements that do not disclose the contents of an invention to the public do
not affect the novelty of the invention, the updated title to § 102 suggests that
such sales are no longer within the scope of § 102.
The Federal Circuit primarily based its Helsinn holding on a two-part
argument. First, the panel held out the premise that private sales were
historically a bar to patentability by referring to the Supreme Court’s holding
in Pennock v. Dialogue.99 The panel then argued that Congress would have
used clearer text if it had wanted to effect a foundational change from this
historical interpretation.100 This argument fails on both counts. Firstly, the
reliance on Pennock is misplaced. Pennock, a case prior to the codification
of the on-sale bar statute, addressed a sale which did disclose the invention
to the public.101 It involved the sale of a new method of connecting two hosepipes intended to reduce leakage.102 While the initial sale of the invention to
a manufacturer was private in nature, the claimed invention was apparent as
soon as products embodying the invention were sold.103 The Supreme Court
confirmed that a patent can be granted for inventions “not known or used by
the public, before the application.”104 The case further states that the patent
law’s grant of a monopoly is not appropriate if the “public were already in
possession and common use of an invention[.]”105 Pennock strongly supports
the proposition that, historically, the on-sale-bar doctrine and its statutory
logic applied only to uses and sales that made the invention available to the
public.106 Secondly, the Federal Circuit argued that since Congress re-used
97. 35 U.S.C. § 102 (2008) (emphasis added).
98. 35 U.S.C. § 102 (2012).
99. Helsinn Healthcare S.A., 855 F.3d at 1369 (“[f]ailing to find such a [private] sale invalidating.
. .would materially retard the progress of science and the useful arts.”) ( quoting Pennock v. Dialogue,
27 U.S. 1, 10 (1829).
100. Id. at 1371 (stating that “[i]f Congress intended to work such a sweeping change to our on-sale
bar jurisprudence and wished to repeal . . . [these prior] cases legislatively, it would do so by clear
language” (internal quotations omitted).
101. See Pennock, 27 U.S. at 14.
102. See Pennock, 27 U.S. 1 at 3.
103. See id.
104. Id. at 19. (emphasis added).
105. Id. at 23 (emphasis added).
106. Dmitry Karshtedt, The Riddle of Secret Public Use: A Response to Professor Lemley, 93 TEX.
L. REV. 159, 163 (2015).
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the term “on-sale” when enacting the AIA, it also intended to re-use the
historical scope for the on-sale bar. This argument is contrary to Supreme
Court precedent that held that the presumption that Congress meant to give
a term its previously held meaning is true only “when it re-enacts a statute
without change.”107 Since the AIA was not a re-enactment, but a large-scale
overhaul of the statute, the panel’s argument is not convincing. Additionally,
the text of the statute was supplemented with the phrase “or otherwise
available to the public,” which is a clear signal of Congress’ intent to remove
private sales from the ambit of the on-sale bar.
An additional glimpse into the Federal Circuit’s reasoning comes from
the concurrence written by Judge O’Malley to the court’s denial of Helsinn’s
petition for en banc review. Judge O’Malley’s primary assertion was that
“on sale” was not modified by the phrase “or otherwise available to the
public.” 108 Instead, the phrase is an independent catch-all provision that
encompasses all other ways an invention can be disclosed to the public.109
While this argument initially seems plausible, it suffers from a fatal flaw. In
articulating her argument, Judge O’Malley only accounted for a part of the
phrase that was added by Congress. The complete phrase states, “or
otherwise available to the public before the effective filing date of the claimed
invention.”110 If Judge O’Malley’s interpretation is correct, even the second
part of the new phrase—“before the effective filing date of the claimed
invention”—would not apply to the terms “on sale,” “in public use,” and
“described in a patented publication.” Thus, a public use or description in a
patented publication will be invalidating even if the use or publication
occurred after the effective filing date of the invention. This is an illogical
result. Therefore, Judge O’Malley’s interpretation cannot be correct.
The policy reason articulated by Judge O’Malley is similarly weak. The
concurrence correctly identifies that the removal of inventions from public
domain was not the only ill intended to be addressed by the on-sale bar.111
The bar was also intended to prevent an unfair extension of the patent
exclusivity period by the inventor. 112 While this would have been a fair
argument in the pre-AIA patent statute, it does not hold water post-AIA. PreAIA, it is conceivable that an inventor could unfairly extend the patent
exclusivity period by not filing a timely patent application. They would be
107. Lorilland v. Pons, 434 U.S. 575, 580 (1978).
108. Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc., Nos. 16-1284, 16-1787, 2018 WL 1583031,
at *3 (Fed. Cir. Jan. 16, 2018) (O’Malley, J., concurring) (applying the last antecedent doctrine).
109. Id.
110. 35 U.S.C. § 102 (2012) (emphasis added).
111. Helsinn Healthcare S.A., 2018 WL 1583031, at *5.
112. Id.
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secure in knowing that their claim would still take priority over a subsequent
inventor who independently invented and applied for a patent on the same
subject matter. The on-sale bar would be a necessary tool to reach the fair
result by denying patent protection to an inventor who had not filed an
application for a year or more after they commercialized their invention. The
AIA, however, replaced the first-to-invent patent system with a first-to-file
system.113 Post-AIA, an inventor who files an application first can obtain a
patent even if their inventive activity occurred later in time.114 Knowing that
another inventor can trump their invention by filing for a patent first removes
the incentive for inventors to delay filing a patent just to extend their
exclusivity period. Thus, the on-sale bar is no longer a necessary tool postAIA to prevent an unfair extension of the patent exclusivity period by
inventors.
The Federal Circuit’s interpretation of the on-sale bar does not find any
support in the text of the statute and does not have any compelling policy
underpinnings. It should, therefore, be reversed. It is also wholly
unsupported by the AIA’s legislative history.
B. THE LEGISLATIVE HISTORY INDICATES THAT THE FEDERAL
CIRCUIT’S INTERPRETATION OF THE ON-SALE BAR UNDERMINES
CONGRESSIONAL INTENT
While not a statement of the law, legislative history can be an extremely
valuable aid in “our understanding of a law.”115 In deciding that the postAIA on-sale-bar included secret sales, the Federal Circuit ignored
compelling legislative history and ignored floor statements from the lead
sponsors of the AIA, Senator Patrick Leahy and Congressman Lamar Smith.
Senator Leahy said that the statute would “do away with precedent under
current law that private offers for sale or private uses of secret processes . . .
may be deemed patent-defeating prior art.”116 His colleague, Congressman
Lamar Smith, concurred, stating: “[C]ontrary to current precedent, in order
to trigger the bar in the new [Section] 102(a) in our legislation, an action
must make the patented subject matter ‘available to the public’ before the
effective filing date.”117

113. Vance Woodward, Patent Innovation: The Leahy-Smith America Invents Act Has Introduced
Many Welcome Reforms to American Patent Law, 38 L.A. LAW. 21, 21 (Mar. 2015).
114. Id.
115. Dig. Realty Tr., Inc. v. Somers, 138 S. Ct. 767, 782 (2018).
116. 157 CONG. REC. 3415 (2011).
117. 157 CONG. REC. 9782 (2011.

2019

THE PATENT ON SALE BAR POST HELSINN AND ITS EFFECT

225

The Federal Circuit not only ignored floor statements, it also discounted
committee reports that the Supreme Court has found to “represen[t] the
considered and collective understanding of those Congressmen involved in
drafting and studying proposed legislation.”118 The AIA, enacted as H.R.
1249, was legislated in response to the House Report H.R. 112-98.119 This
report, which neither of the Federal Circuit opinions considered, states that
“the phrase ‘available to the public’ is added to clarify the broad scope of
relevant prior art, as well as to emphasize the fact that it must be publicly
accessible.”120 The House Report, H.R. 112-98, also states in its discussion
related to § 102(a)(1) that “[p]rior art . . . will typically include all art that
publicly exists prior to the filing date, other than disclosures by the inventor
within 1 year of filing.” 121 Similar sentiments are also expressed in the
Senate Colloquies that documents opinions presented by senators who
sponsored the AIA. Senator Kyl specifically warned against the type of
interpretation that the Federal Circuit reached by saying “[a] contrary
construction of section 102(a)(1), which allowed private and non-disclosing
uses and sales to constitute invalidating prior art, would be fairly disastrous
for the U.S. patent system.”122 Senator Leahy stated his understanding that
“disclosure” under § 102(a)(1) is synonymous with “public disclosure.”123
Senator Leahy further clarified by saying that “and by a ‘public disclosure’
I mean one that results in the claimed invention being ‘described in a printed
publication, or in public use, on sale, or otherwise available to the public.’”124
These statements from sponsors of the Leahy-Smith bill, supported by
the finding of the House Report, provide compelling evidence that Congress
made a conscious decision while updating the definition of prior art in
§102(a)(1) to remove non-disclosing, non-public sales from the category of
invalidating prior art. This evidence is further strengthened by the complete
absence of any floor statements, or recorded opinions of Senators or
Congressmen, opposing this stance.

118.
119.
120.
121.
122.
123.
124.

Garcia v. United States, 469 U.S. 70, 76 (1984) (alteration in original).
H.R. REP. No. 112-98, pt. 1, at 1 (2011).
Id. at 43 (emphasis added).
Id. at 42 (emphasis added).
157 CONG. REC. 3424 (2011).
157 CONG. REC. 3415 (2011).
Id.
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C. THE ON-SALE BAR FOR NON-PUBLIC SALES IS OUT OF SYNC
WITH INTERNATIONAL PATENT LAWS
The “sense of Congress” provisions in the AIA state that one of its goals
is to “promote greater international uniformity and certainty in the
procedures. . .”125 The Federal Circuit’s interpretation that a non-public sale
can trigger a bar to patentability is in direct opposition to this stated goal. A
review of the patent systems in other major jurisdictions, that along with the
United States account for 90 percent of worldwide patent filings,126 shows
that forfeiture of patent rights due to commercial transactions that do not
publicly disclose the invention is unique to the U.S. patent system. A quick
summary is presented below for prior art definitions in the non-U.S. IP5127
countries.
Europe: European patent law does not envision something as prior art
unless it is “available to the public . . . by use, or in any other way . . . before
the date of filing of the European patent application.”128 The European Patent
Board of Appeals demonstrated this principle by holding that the sale of a
microchip containing the inventive program did not constitute invalidating
prior art when “the principle underlying [invention] is not discernible [to the
public] by inspection.”129
China: In Chinese patent law, prior art encompasses inventions that are
“known to the public both domestically and abroad before the date of
application.” 130 The disclosure of an invention made by selling an
embodiment can only serve as prior art if it makes the “technical content
available to the public.”131

125. Leahy-Smith America Invents Act, H.R. 1249, 112th Cong. § 3(p) (2011-2012).
126. See
IP5,
USPTO,
https://www.uspto.gov/patents-getting-started/internationalprotection/office-policy-and-international-affairs-ip5 (last visited Apr. 28, 2018) (identifying Europe,
China, Korea and Japan as the five largest intellectual property offices in the world which account for 90
percent of all patent filings).
127. Id.
128. Convention on the Grant of European Patents art. 54(2), Oct. 5, 1973, 1065 U.N.T.S. 199
(emphasis added).
129. EPO Case Number T 0461/88 (Apr. 17, 1991), available at http://www.epo.org/lawpractice/case-law-appeals/recent/t880461ep1.html#q.
130. Patent Law of the People’s Republic of China, art. 22 (1984) (amended Dec. 2008), available at
http://english.sipo.gov.cn/laws/lawsregulations/201101/t20110119_566244.html.
131. Guidelines for Patent Examination, (promulgated by the State Intellectual Property Office of the
People’s
Republic
of
China,
2010),
ch.
3
§
2.1.2.2,
available
at
http://www.sipo.gov.cn/zlsqzn/sczn2010eng.pdf (China).
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South Korea: South Korea defines prior art as an invention that is
“publicly known or executed in the Republic of Korea. . .” 132 where the
definition of “executed” includes the act of selling the invention.133
Japan: Japan utilizes a definition like South Korea for prior-art
“inventions that were publicly known in Japan [or] publicly worked in Japan
or a foreign country, prior to the filing.” 134 The definition of “working”
includes “producing, using, assigning, etc.”135
Helsinn’s interpretation of the on-sale bar is unlike that in any of the
other IP5 countries. It, therefore, cuts against Congress’ stated intent to
harmonize the U.S. Patent system with the rest of the world. The Federal
Circuit’s interpretation of the on-sale bar, as exemplified in Helsinn, is
contrary to the AIA’s text, legislative history, and Congressional intent. It is,
however, the applicable law until the Supreme Court or Congress steps in to
overrule Helsinn. Pharma companies should be cautious about structuring
any license and supply agreements so that they do not trigger the on-sale bar
as per Federal Circuit’s current case law.
V. TIPS TO NAVIGATE THE CURRENT ON-SALE-BAR MINEFIELD
The Helsinn decision has not only made it harder for small pharma
companies to raise capital, it has also injected uncertainty into otherwise
routine commercial transactions. Post-Helsinn, the on-sale bar inquiry is
extremely fact specific where “[e]ach case [is] decided based on its own
facts.”136 Helsinn did, however, identify some common factors in Federal
Circuit decisions where the on-sale bar was found not to be applicable. It
noted that “the absence of the passage of title, the confidential nature of a
transaction, and the absence of commercial marketing of the invention all
counsel against applying the on-sale bar.” 137 Similarly, the Medicines
decision found that the “absence of title transfer [and] the confidential nature
of the transactions” counsels against application of the on-sale bar even
though it is not of “talismanic significance.”138 Utilizing the common factors

132. Patent Act, Act No. 950, Dec. 31, 1961, amended by Act. No. 14112, Mar. 29, 2016, art. 29(1)
(S.Kor.).
133. Id. at art. 2(3).
134. Tokkyoh [Patent Act], Law No. 121 of 1959, amended by Law No. 36 of 2014, art. 29(1)
(Japan).
135. Id. at art. 2(3).
136. Helsinn Healthcare S.A., 855 F.3d at 1371.
137. Id. at 1364.
138. Meds. Co. v. Hospira, Inc., 827 F.3d 1363, 1376 (Fed. Cir. 2016).
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noted in Helsinn and Medicines, this section will provide some suggestions
on how to structure transactions to sidestep the on-sale bar minefield.
A. AVOIDING TITLE TRANSFER MAY AVOID TRIGGERING THE ONSALE BAR
Federal Circuit case law has consistently looked to the UCC to
determine what activities constitute “sale.” 139 The UCC defines sale as
“passing of title from the seller to the buyer for a price.” 140 The Federal
Circuit panel in Helsinn found that the supply agreement drafted by the
parties triggered the on-sale bar as it “expressly contemplated” the passage
of title.141 In contrast, the Federal Circuit en banc found that a manufacturing
services agreement did not trigger the on-sale bar because there was an
“absence of title transfer.”142 Similarly, transactions that resemble “potential
or eventual marketing,” rather than “actual commercial marketing” of
inventions, do not trigger the on-sale bar.143
Therefore, license agreements and distribution services agreements that
allow investors to derive commercial benefit from a patent without
transferring title can be used to avoid the on-sale bar. Federal Circuit caselaw differentiates between transactions that transfer legal rights in the
invention from ones that transfer title in products embodying the
invention. 144 For example, a license agreement that transferred process
know-how and contemplated the sale of “resultant products” manufactured
by the licensee did not trigger the on-sale bar. 145 Similarly, the Federal
Circuit has found that transfer of “production rights in the invention”146 or
“the exclusive right to market the invention” is not a sale of the invention
itself, and therefore does not trigger the on-sale bar. While it avoids the onsale bar minefield, the licensing agreement approach has other limitations.
Getting a license to a technology is not the same as getting a commercial
product, and the licensee must still invest in infrastructure to produce a
139. Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc., Nos. 16-1284, 16-1787, 2018 WL 1583031,
at *2 (Fed. Cir. Jan. 16, 2018).
140. U.C.C. § 2-106 (AM. LAW INST. & UNIF. LAW COMM’N 2002).
141. Helsinn Healthcare S.A., 855 F.3d at 1364.
142. Meds. Co., 827 F.3d at 1375.
143. Id. at 1377.
144. Grp. One, Ltd. v. Hallmark Cards, Inc., 254 F.3d 1041, 1049 (Fed. Cir. 2001) (“. . . a sale of
rights in a patent, as distinct from a sale of the invention itself, is not within the scope of the statute, and
thus does not implicate the on-sale bar.”); id. at 1052 (Lourie, J., additional comments) (“A license is
analogous to granting or waiving rights under the patent, which is distinct from selling the machine
covered by the patent.”).
145. In re Kollar, 286 F.3d 1326, 1330 (Fed. Cir. 2002).
146. Id. at 1331 (citing Mas-Hamilton Grp. v. LaGard, Inc., 156 F.3d 1206 (Fed. Cir. 1998)).
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sellable product. While some licensees may be open to such an investment,
others may still prefer to directly obtain sellable units from the inventor.
Similarly, a distribution services agreement leaves the title, and therefore
risk of the product, with the inventor and may be less preferable to a sale
agreement where the risk of the product transfers to the buyer upon delivery
of the product.
B. AN INDEFINITE AGREEMENT FOR FUTURE SALES MAY NOT
TRIGGER ON-SALE
Some licensees/investors do not wish to manufacture the patented
product themselves. As a result, it is common to pair a license agreement
with a future supply agreement where the inventor manufactures and
supplies products that the licensee can sell. If a future supply agreement
contains definite terms, it may qualify as an “offer for sale” and therefore
trigger the on-sale bar. A case in point is Helsinn where a letter of intent
(“LOI”) that contained “specific terms, such as price, method of payment,
and method of delivery . . . constituted a commercial sale or offer for sale for
purposes of [on-sale bar].”147 Conversely, agreements that do not contain all
terms required for a definitive agreement do not trigger the on-sale bar, as
seen in Elan Corp., PLC v. Andrx Pharm., Inc.148 The transaction in Elan
Corp. was structured with an upfront license/royalty fee with payments tied
to the inventor achieving certain milestones such as filing the New Drug
Application, approval by the FDA and patient enrollment in the clinical
study. As is common in such deals, the license agreement was paired with a
future supply agreement. The inventor agreed to supply the patented drug
product to the licensee at a bulk price that allowed an “initial gross margin
based on current [drug] prices of not less than 70 percent after taking into
account [the] processing charge.” 149 The Federal Circuit noted that this
agreement “lacked any mention of quantities, time of delivery, place of
delivery”150 and “[u]ntil the formulation had been finalized . . . there was no
way it could [be] determined what . . . the offering price would be.”151 The
on-sale bar was not triggered in this case due to the lack of specificity in the
agreement.152 The opposite outcome occurred in a different case where an
inventor agreed to provide the investor with a fixed percentage of their
147.
148.
149.
150.
151.
152.

Helsinn Healthcare S.A. v. Teva Pharm. USA, Inc., 855 F.3d 1356, 1365–67 (Fed. Cir. 2017).
366 F.3d 1336, 1342 (Fed. Cir. 2004).
Id. at 1338.
Id. at 1341.
Id. at 1342.
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worldwide requirements (quantity term) at reasonably competitive prices
(price term). 153 Here, the agreement was found to be specific enough to
qualify as an offer for sale, thus triggering the on-sale bar.154 The Federal
Circuit has summarized this distinction by stating that an agreement for
future supply “rises to the level of a commercial offer for sale” when it
contains all necessary contractual terms and a party “could make [it] into a
binding contract by simple acceptance.”155
These cases suggest that LOIs that stop short of defining all terms
required to give rise to a binding contract may avoid triggering the on-sale
bar. LOIs can be a valuable tool to document the present agreement between
the parties and create a jumping-off point for future negotiations. LOIs can
document the terms that the parties have already agreed to and leave some
terms for the parties to negotiate after the patent application has been filed.156
Any concerns regarding the enforceability of an LOI during future
negotiations can be alleviated through the inclusion of a “good-faith
negotiation” clause.157 Good-faith negotiation clauses are enforced by courts
and obligate both parties to conduct future negotiations in good faith and in
accordance with agreed-upon terms that are documented in the LOI. 158
Therefore, use of LOIs can enable parties to proceed with a transaction by
agreeing on critical terms while leaving the overall agreement indefinite until
a patent application is filed, thus side-stepping the on-sale bar minefield.
VI. CONCLUSION
The Federal Circuit’s interpretation of the on-sale bar is not only built
on a faulty legal rationale, it also defies any discernible public policy. In
reaching this faulty interpretation, the Federal Circuit misread the statutory
text of 35 U.S.C. § 102 and refused to take advantage of the AIA’s legislative
history. The Federal Circuit’s reasoning also discounts Congress’ conscious
decision to add a new phrase “or otherwise available to the public” to the
definition of prior-art. In negating the changes introduced by the AIA,
Helsinn particularly injures small pharma companies by hurting their ability
to obtain early-stage funding. By making it harder for small pharma
companies to keep producing innovative new drugs, this decision not only
hurts the industry but also puts patients at a disadvantage. Until the Supreme
153.
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Court reverses Helsinn, and provides a more practical application of the onsale bar, companies should carefully structure their supply agreements,
manufacturing agreements, and license deals to avoid triggering the on-sale
bar. Entering into license and distribution services agreements that avoid
transfer of title may avoid application of the on-sale bar. Similarly, using
LOIs that leave some terms open for future negotiation instead of entering
into definitive contracts may avoid triggering the on-sale bar.

